Completed PHASE2 INTERVENTIONAL NCT00214110

Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]

Phase 2 Randomized Single-blind Escalating Dose Response Clinical Trial of Tamoxifen Therapy on Mean Percent Predicted Isometric Strength in Amyotrophic Lateral Sclerosis [ALS]

Sponsor: University of Wisconsin, Madison

Conditions Amyotrophic Lateral Sclerosis (ALS)

Interventions Tamoxifen

Updated 6 times since 2017 Last updated: Oct 1, 2015 Started: Jan 31, 2001 Completion: Jan 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Amyotrophic Lateral Sclerosis (ALS) and is currently completed. University of Wisconsin, Madison leads this study, which shows 6 recorded versions since 2001 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Wisconsin, Madison

Data source: University of Wisconsin, Madison

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Madison, United States